Frost & Sullivan IDs Five New Technologies to Power Research Across Preclinical Disease Models Published: July 16, 2020 BioSpace When the CEOs of young, innovative biotech companies discuss how their new technologies came to be, they almost inevitably mention a convergence of technologies that was pivotal in transforming an idea into a therapeutic, diagnostic, tool […]

The U.S. Food and Drug Administration granted clearance for Akili’s EndeavorRx as a prescription treatment for children with attention deficit hyperactivity disorder (ADHD).

The online publication NEO.LIFE pointed to seven areas where biotech companies and researchers have significant potential to “dramatically reshape our concept of what it means to be human.”

While some manufacturing industries have long utilized automation throughout their processes and product production, the biopharma industry is comparatively behind the times.

A new computer tool has been developed to predict how some cancers may respond to an investigational treatment before the drug has even been administered to a patient.

Heart devices that use software or wireless communications may be vulnerable to hacker attacks that could cause life-threatening malfunctions, U.S. cardiologists say.

Celgene entered into a partnership to take on autoimmune diseases with two of New Jersey-based Nimbus Therapeutics’ preclinical therapeutics.

AstraZeneca forged a research collaboration with Boston-based Berg, a specialist in artificial intelligence for drug hunting.

The general public’s help is being enlisted in what is believed to be the largest study of the human microbiome – the bacteria that live in and on the human body – and are believed to affect health.

Artificial intelligence robots are turbo-charging the race to find new drugs for the crippling nerve disorder ALS, or motor neurone disease.